Ardelyx (ARDX) news
Recent news
Immix Biopharma prices offer of 11.36M sharees at $11 each
Immix Biopharma has announced the pricing of its recent share offering, which includes 11.36 million shares priced at $11 per share. The offering is part of the company’s ongoing efforts to raise capital for research and development initiatives. No further details regarding the use of proceeds or…
AInvest Wire · Sep 29, 2026Trading released/resumed: (ADRX) Reason not available
Trading in shares of Ardelyx, Inc. (NASDAQ: ARDX) has resumed following a prior suspension, though the specific reason for the halt has not been disclosed by the company or the exchange. The resumption of trading allows investors to once again transact in the stock, though market participants are…
AInvest Wire · Sep 25, 2026Tempest Therapeutics appoints Drake Richey and John Yee, MD, MPH to board of directors
Tempest Therapeutics has announced the appointment of Drake Richey and John Yee, MD, MPH, to its board of directors, expanding its leadership team as the company continues to advance its therapeutic pipeline and strategic initiatives. The additions follow a period of significant growth and…
AInvest Wire · Jun 4, 2026US FDA approves Ardelyx's kidney disease-related drug
The U.S. Food and Drug Administration (FDA) has approved Ardelyx’s drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more than two years after it was initially rejected.
AInvest Wire · Oct 17, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.